Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1492-1493; doi:10.1093/jnci/93.19.1492-a
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hemstreet, G. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hemstreet, G. P., III
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1492-1493, October 3, 2001
© 2001 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine

George P. Hemstreet, III

Correspondence to: George P. Hemstreet III, M.D., Ph.D., 1009 Outabounds Dr., Edmond, OK 73034 (e-mail: gphemstreet@hotmail.com).

The comments by Dr. Nersesyan regarding cytogenetic biomarkers focus on a number of frequently underappreciated issues related to biomarker research. However, a central theme of the comments and our published work (1) is biomarker specificity and sensitivity. Potential biomarkers for bladder cancer, including chromosomal aberrations, and a meta-analysis of the more frequently used biomarkers have recently been reviewed (2,. . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?